PM
PRIMECAP MANAGEMENT CO/CA/
PRIMECAP MANAGEMENT CO/CA/ · Investor
1Y performance ⓘ
+63%
AUM (13F)
$127.0B
# of Holdings
320
3Y performance ⓘ
+107%
vs S&P 500 ⓘ
+28%
Updated
Mar 31
PRIMECAP MANAGEMENT CO/CA/'s PRIMECAP MANAGEMENT CO/CA/ holds 320 U.S.-equity positions worth $127.0B (SEC 13F, Q1 2026). Top positions: Eli Lilly & Co. 6.7%, Micron Technology, Inc. 5.8%, Alphabet Inc. Class A Common Stock 3.4%. 13F-replication return is +107% over 3 years (+28 pts vs the S&P 500) — a replicated, non-audited figure.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | 6.7% | 9.2M | $8.5B | — | $343.42 | $1,150.39 (+235%) | 2026-03-31 |
| MU Micron Technology, Inc. | 5.8% | 21.9M | $7.4B | ▼ 12% (−2.9M) | $60.76 | $1,062.39 (+1649%) | 2026-03-31 |
| GOOGL Alphabet Inc. Class A Common Stock | 3.4% | 15.0M | $4.3B | ▼ 0.9% (−141K) | $105.29 | $344.90 (+228%) | 2026-03-31 |
| AZN AstraZeneca PLC | 2.8% | 18.2M | $3.6B | NEW (+18.2M) | $197.22 | $160.71 (−19%) | 2026-03-31 |
| KLAC KLA Corporation Common Stock | 2.8% | 2.4M | $3.6B | ▼ 15% (−438K) | $39.92 | $198.82 (+398%) | 2026-03-31 |
| INTC Intel Corp | 2.6% | 75.8M | $3.3B | — | $32.60 | $119.69 (+267%) | 2026-03-31 |
| AMGN Amgen Inc | 2.5% | 8.9M | $3.1B | — | $241.78 | $419.62 (+74%) | 2026-03-31 |
| NVDA NVIDIA CORP | 2.4% | 17.2M | $3.0B | — | $27.78 | $230.82 (+731%) | 2026-03-31 |
| FDX FedEx Corporation | 2.3% | 8.3M | $3.0B | ▼ 2.5% (−210K) | $228.49 | $284.99 (+25%) | 2026-03-31 |
| BIIB Biogen Inc. Common Stock | 2.1% | 14.8M | $2.7B | — | $277.41 | $225.46 (−19%) | 2026-03-31 |
| MSFT MICROSOFT CORP | 2.1% | 7.3M | $2.7B | — | $288.95 | $519.35 (+80%) | 2026-03-31 |
| AMZN Amazon.Com Inc | 2.0% | 12.1M | $2.5B | ▼ 1.2% (−149K) | $179.72 | $249.66 (+39%) | 2026-03-31 |
| BABA Alibaba Group Hldg Ltd | 1.9% | 18.7M | $2.3B | ▼ 1.3% (−255K) | $96.26 | $108.85 (+13%) | 2026-03-31 |
| TSLA Tesla, Inc. | 1.8% | 6.1M | $2.3B | ▼ 3.0% (−192K) | $207.46 | $355.59 (+71%) | 2026-03-31 |
| SCHW The Charles Schwab Corporation | 1.7% | 23.4M | $2.2B | ▲ 0.7% (+166K) | $82.94 | $97.72 (+18%) | 2026-03-31 |
| BSX Boston Scientific Corp. | 1.6% | 32.5M | $2.0B | ▲ 4.6% (+1.4M) | $50.73 | $43.49 (−14%) | 2026-03-31 |
| ROST Ross Stores Inc | 1.6% | 9.2M | $2.0B | — | $106.24 | $232.94 (+119%) | 2026-03-31 |
| TXN Texas Instruments Incorporated | 1.5% | 9.7M | $1.9B | ▼ 4.3% (−430K) | $186.01 | $280.60 (+51%) | 2026-03-31 |
| LUV Southwest Airlines Co. | 1.4% | 47.1M | $1.8B | ▼ 0.7% (−323K) | $32.50 | $41.62 (+28%) | 2026-03-31 |
| FLEX Flex Ltd. Ordinary Shares | 1.3% | 25.4M | $1.7B | ▼ 4.9% (−1.3M) | $23.09 | $109.76 (+375%) | 2026-03-31 |
| GOOG Alphabet Inc. Class C Capital Stock | 1.3% | 5.7M | $1.6B | ▼ 0.7% (−42K) | $104.00 | $341.94 (+229%) | 2026-03-31 |
| TJX TJX Companies, Inc. (The) | 1.2% | 9.6M | $1.5B | ▼ 1.5% (−150K) | $78.36 | $132.22 (+69%) | 2026-03-31 |
| COP ConocoPhillips | 1.2% | 11.6M | $1.5B | — | $102.75 | $125.34 (+22%) | 2026-03-31 |
| BMY Bristol-Myers Squibb Co. | 1.2% | 25.0M | $1.5B | — | $65.27 | $62.48 (−4%) | 2026-03-31 |
| ONC Beone Medicines Ltd | 1.2% | 5.0M | $1.5B | — | $271.98 | $367.98 (+35%) | 2026-03-31 |
| UAL United Airlines Holdings, Inc. Common Stock | 1.1% | 15.8M | $1.5B | ▼ 1.4% (−228K) | $44.31 | $110.17 (+149%) | 2026-03-31 |
| GSK Gsk Plc | 1.1% | 25.2M | $1.4B | — | $35.67 | $48.09 (+35%) | 2026-03-31 |
| RJF Raymond James Financial, Inc. | 1.1% | 9.3M | $1.4B | — | $95.07 | $157.61 (+66%) | 2026-03-31 |
| BIDU Baidu Inc | 1.0% | 11.1M | $1.2B | — | $136.75 | $87.56 (−36%) | 2026-03-31 |
| V VISA Inc. | 1.0% | 4.1M | $1.2B | ▲ 1.3% (+51K) | $237.89 | $361.52 (+52%) | 2026-03-31 |
| SONY Sony Group Corp | 0.9% | 58.5M | $1.2B | — | $18.14 | $23.66 (+30%) | 2026-03-31 |
| DAL Delta Air Lines, Inc. | 0.9% | 17.5M | $1.2B | — | $35.13 | $83.35 (+137%) | 2026-03-31 |
| NVS Novartis Ag | 0.9% | 7.6M | $1.2B | — | $92.05 | $142.10 (+54%) | 2026-03-31 |
| ADBE Adobe Inc. | 0.9% | 4.7M | $1.1B | ▲ 29% (+1.1M) | $353.65 | $245.33 (−31%) | 2026-03-31 |
| ELAN Elanco Animal Health Incorporated Common Stock | 0.9% | 45.8M | $1.1B | ▼ 0.8% (−373K) | $10.05 | $22.30 (+122%) | 2026-03-31 |
| JPM JPMorgan Chase & Co. | 0.8% | 3.4M | $1.0B | ▼ 5.6% (−203K) | $144.50 | $330.16 (+128%) | 2026-03-31 |
| ADI Analog Devices, Inc. | 0.8% | 3.1M | $998M | — | $197.22 | $397.12 (+101%) | 2026-03-31 |
| TMO Thermo Fisher Scientific, Inc. | 0.8% | 2.0M | $974M | ▼ 3.6% (−75K) | $570.06 | $670.23 (+18%) | 2026-03-31 |
| NTAP NetApp, Inc | 0.7% | 9.1M | $927M | — | $63.85 | $209.69 (+228%) | 2026-03-31 |
| NTRS Northern Trust Corp | 0.7% | 6.5M | $914M | ▼ 0.9% (−59K) | $93.00 | $169.60 (+82%) | 2026-03-31 |
| JBL Jabil Inc. | 0.7% | 3.3M | $872M | ▼ 1.9% (−63K) | $90.30 | $289.10 (+220%) | 2026-03-31 |
| ORCL Oracle Corp | 0.7% | 5.7M | $835M | ▼ 5.9% (−358K) | $97.48 | $138.05 (+42%) | 2026-03-31 |
| NXT Nextpower Inc. Class A Common Stock | 0.6% | 6.8M | $815M | ▼ 2.7% (−191K) | $53.83 | $78.18 (+45%) | 2026-03-31 |
| BMRN BioMarin Pharmaceuticals Inc | 0.6% | 14.2M | $802M | ▼ 2.4% (−355K) | $96.82 | $59.72 (−38%) | 2026-03-31 |
| ACM Aecom | 0.6% | 8.6M | $733M | — | $84.32 | $59.38 (−30%) | 2026-03-31 |
| RCL Royal Caribbean Group | 0.5% | 2.3M | $646M | ▼ 2.6% (−64K) | $65.30 | $266.13 (+308%) | 2026-03-31 |
| IEX IDEX Corporation | 0.5% | 3.3M | $626M | ▲ 2.4% (+76K) | $176.77 | $228.53 (+29%) | 2026-03-31 |
| CAT Caterpillar Inc. | 0.5% | 872K | $618M | ▼ 0.9% (−8K) | $228.84 | $810.46 (+254%) | 2026-03-31 |
| WFC Wells Fargo & Co. | 0.5% | 7.7M | $615M | ▼ 7.6% (−637K) | $37.38 | $79.50 (+113%) | 2026-03-31 |
| DIS The Walt Disney Company | 0.5% | 6.2M | $601M | — | $100.01 | $103.45 (+3%) | 2026-03-31 |
Showing top 50 of 320 holdings by value.
FAQ ▾
What are PRIMECAP MANAGEMENT CO/CA/'s largest holdings?
As of the latest 13F: Eli Lilly & Co. 6.7%, Micron Technology, Inc. 5.8%, Alphabet Inc. Class A Common Stock 3.4%, AstraZeneca PLC 2.8%, KLA Corporation Common Stock 2.8%.
How big is PRIMECAP MANAGEMENT CO/CA/'s 13F portfolio?
$127.0B across 320 disclosed U.S.-equity positions.
What is PRIMECAP MANAGEMENT CO/CA/'s 3-year performance?
+107% (13F-replication, price return), +28 pts vs the S&P 500. Not an audited fund return.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.